Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| DAIO | Data I/O | $2.97 | $0.22 | 740.74% | 50 | $28M | $1.88$3.57 |
| EUDA | Euda Health | $1.92 | $0.56 | 41.18% | 40.2K | $73M | $1.03$4.70 |
| AFJK | Aimei Health Technology | $44.01 | $12.00 | 37.49% | 37.5K | $269M | $6.75$98.15 |
| IZM | Iczoom Group | $1.80 | $0.20 | 12.50% | 14.9K | $22M | $0.87$2.74 |
| LFMD | LifeMD | $3.46 | $0.26 | 8.13% | 64.5K | $167M | $3.18$15.84 |
| ESHA | Esh Acquisition Corp. | $12.24 | $0.59 | 5.06% | 1.8K | $48M | $10.76$14.75 |
| EWTX | Edgewise Therapeutics | $21.75 | $0.81 | 3.84% | 39.3K | $2.3B | $10.60$30.48 |
| ALCY | Alchemy Investments Acquisition Corp 1 | $12.06 | $0.30 | 2.55% | 985 | $51M | $10.25$14.00 |
| DVAX | Dynavax Technologies | $11.13 | -$0.03 | -0.27% | 4.6M | $1.3B | $9.20$14.63 |
| CRDF | Cardiff Oncology | $2.91 | -$0.01 | -0.34% | 522 | $196M | $1.90$4.99 |
Related Articles
Featured Article
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
George Budwell, PhD|Aug 16, 2023
This small-cap biotech stock holds enormous growth potential.
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
Alex Carchidi|Mar 26, 2023
This company plans to be profitable soon, and its revenue is already spiking.
2 Stocks That Could Rebound and Rise 30% or More in 2023
Alex Carchidi|Mar 10, 2023
They're down, but they aren't yet out.
Advertisement
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
These 2 Nasdaq Stocks Are Poised to Make Big Moves Today
George Budwell, PhD|Jan 19, 2022
These clinical-stage biotech stocks are headed in opposite directions today.
1 Cancer Stock on Buyout Watch in 2022
George Budwell, PhD|Nov 21, 2021
Cardiff Oncology is a prime takeover target heading into 2022.
Will Valneva and Dynavax Score With Their Late-to-the-Party COVID Vaccine?
Keith Speights and Brian Orelli, PhD|Oct 29, 2021
There's still a sizable market opportunity, especially in developing nations.
How Will Valneva's COVID Vaccine Setback Impact Dynavax?
Keith Speights and Brian Orelli, PhD|Sep 25, 2021
It's definitely not a showstopper for the biotech or its CpG 1018 adjuvant.
2 Biotech Stocks ARK Invest Bought in June
Cory Renauer|Jun 7, 2021
Should you follow Cathie Wood's latest genomic revolution investments?
How Dynavax Demolished Expectations With Its Q1 Results
Keith Speights|May 7, 2021
The company's hepatitis B vaccine wasn't its key growth driver.
